文献速递湿疹皮炎与荨麻疹

利格利珠单抗耗竭IgE对中重度特应性皮炎症状无显著改善

IgE Depletion with Ligelizumab Does Not Significantly Improve Clinical Symptoms in Patients with Moderate-to-Severe Atopic Dermatitis.
PubMed 文献 · J Invest Dermatol · 2023-03-31

该随机、多中心、双盲、安慰剂与环孢素A对照的12周试验纳入22例中重度特应性皮炎成人患者,评估高亲和力抗IgE抗体利格利珠单抗(280 mg皮下注射,每两周一次)的安全性与疗效。结果显示利格利珠单抗可完全或部分抑制血清及细胞结合IgE,但在EASI 50应答、瘙痒及睡眠障碍改善方面未显著优于安慰剂,而环孢素A则不然。作者认为免疫学有效的抗IgE策略治疗特应性皮炎未明确优于安慰剂,需更大规模研究确定特定亚组是否获益。

要点

  • 利格利珠单抗280 mg皮下注射每两周一次,可完全或部分抑制血清及细胞结合IgE。
  • 利格利珠单抗在EASI 50应答、瘙痒及睡眠障碍改善方面未显著优于安慰剂。
  • 基线IgE高的患者治疗应答略优于基线IgE低者,但未达统计学显著。

核心结论

  • 免疫学有效的抗IgE策略治疗特应性皮炎未明确优于安慰剂,需更大规模研究确定特定患者亚组是否可能获益。

研究设计与样本

  • 随机、多中心、双盲、安慰剂与活性药(环孢素A)对照临床试验,为期12周,纳入22例中重度特应性皮炎成人患者。

主要发现

  • 利格利珠单抗导致血清及细胞结合IgE完全抑制(基线IgE<1500 IU/ml的患者)或部分抑制(基线IgE>1500 IU/ml的患者),并抑制过敏性皮肤点刺试验。
  • 利格利珠单抗在诱导湿疹面积和严重度指数50应答或显著减轻瘙痒及睡眠障碍方面未显著优于安慰剂,而环孢素A则不然。
  • 基线IgE高的患者治疗应答略优于基线IgE低者,但未达统计学显著。

关键数值与推荐

  • 利格利珠单抗剂量为280 mg皮下注射,每两周一次。
  • 基线IgE<1500 IU/ml的患者获完全抑制,基线IgE>1500 IU/ml的患者获部分抑制。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需更大规模研究确定特定患者亚组是否可能从该策略获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The value, if any, of anti-IgE approaches in the treatment of atopic dermatitis has not been fully clarified. Studies using the anti-IgE omalizumab have yielded conflicting results. OBJECTIVE: Antibodies with an IgE-suppressive capacity stronger than omalizumab might be more efficacious. STUDY DESIGN: We assessed the safety and efficacy of the high-affinity anti-IgE antibody ligelizumab (280 mg, subcutaneous, every other week) in 22 adult patients with moderate-to-severe atopic dermatitis in a placebo and active (cyclosporine A) controlled, randomized, multicenter, double-blind clinical trial for 12 weeks. RESULTS: We found that ligelizumab treatment resulted in either complete (patients with baseline IgE < 1,500 IU/ml) or partial (baseline IgE > 1,500 IU/ml) suppression of serum and cell-bound IgE as well as of allergic skin prick tests. On the other hand, ligelizumab-as opposed to cyclosporine A-was not significantly superior to placebo in inducing Eczema Area and Severity Index 50 response or significantly reducing pruritus and sleep disturbance. Interestingly though, patients with high baseline IgE exhibited a slightly but not significantly better treatment response than those with low baseline IgE. CONCLUSION: Our study shows that an immunologically efficacious anti-IgE approach is not clearly superior to placebo in treating atopic dermatitis. Larger studies are needed to determine whether certain patient subgroups may benefit from this strategy. TRIAL REGISTRATION: The study was registered in 2011 at clinicaltrialsregister.eu, EudraCT Number 2011-002112-84.

来源:J Invest Dermatol,查看原文。版权归原作者所有。

引用

  1. Bangert C, Loesche C, Skvara H, et al. IgE Depletion with Ligelizumab Does Not Significantly Improve Clinical Symptoms in Patients with Moderate-to-Severe Atopic Dermatitis. J Invest Dermatol. 2023. PMID: 37004878. doi:10.1016/j.jid.2023.01.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。